You can almost hear the sound of salad forks being dropped…
The billion-dollar skinny shot club just got a surprise guest – and it didn’t knock – it just waltzed in and took a seat at the table.
In a world where shedding pounds has become more lucrative than printing money – someone finally figured out how to mix “miracle drug” with “discount aisle.”
If the established players were sipping champagne – they might want to switch to black coffee…
Because when one market opens the floodgates – and we’re talking over 600 million potential customers – the game doesn’t just change.
It gets flipped, stretched and slimmed down for mass appeal.
In case you haven’t figured it out – we’re talking about GLP-1 peptide shots found in Zepbound and Wegovy.
This drug is changing the face of fitness – literally – as people have been using these drugs to drop pounds like Liz Taylor dropped husbands.
So, who’s the new player?
Even more, what does this mean for the weight loss industry as a whole?
Let’s get into it…
Weight-loss giants Eli Lilly (LLY) and Novo Nordisk (NVO) have dominated the fat-fighting pharmaceutical frontier for years now…
But that may all be changing because this week – Chinese regulators approved the country’s first major homegrown rival: Innovent Biologics’ “mazdutide” a GLP-1 drug that’s stepping into the ring with the established heavyweights.
And make no mistake – this isn’t just a symbolic nod to China’s biotech ambitions…
It’s a shot across the bow of two of the most valuable drugmakers in the world.
With over 600 million Chinese adults projected to be overweight by 2050 – the stakes are colossal. China is shaping up to be one of the largest – and most lucrative – obesity markets on the planet…
And with Novo based in Denmark and Lilly headquartered in the US – Innovent Biologics (traded in Hong Kong under 1801.HK) could gain major traction on home turf.
That hometown advantage might be the secret ingredient in this new recipe for competition.
For now, Novo Nordisk still holds a trump card: the patent for semaglutide – the compound behind Wegovy and Ozempic – is still intact in China…
But the clock’s ticking.
That patent is set to expire in 2026 – and when it does – China’s generics game is likely to go into overdrive.
Several domestic companies are already working on biosimilars and GLP-1 alternatives that mimic semaglutide’s action – and over 30 anti-obesity drugs are currently in clinical development within China.
If even a fraction of those proves successful – the dynamic of the global weight-loss drug market could shift fast.
These drugs aren’t just popular – they’re cash cows…
Bringing in billions in profit margins thanks to their premium pricing and sky-high demand. But as China ramps up production and slashes prices – the days of unchecked profit growth for NVO and LLY could be numbered.
And this isn’t just a pharma story – it’s part of a much broader Chinese playbook…
Disrupt global markets with scale, speed and cost-cutting precision.
We’ve already seen it in the tech sector.
Take Baidu (BIDU) as an example.
The company recently opened up its Ernie chatbot platform to developers – and made it completely free.
That’s a direct challenge to paid tools like ChatGPT…
Forcing global competitors to either drop prices, innovate faster, or risk getting steamrolled.
This is what China does best: flood the field, lower the price floor and challenge the status quo…
And with the global obesity drug market expected to top $100 billion by the end of the decade – there’s every incentive for Chinese companies to rush in.
Whether they win or not?
That’s up to the results in the lab – and the response on Wall Street.
Which is why investors are making moves now in order to get positioned correctly.
The question: is now the right time?
They’d know if they were members of GorillaTrades. Our trading matrix is supported by one thing and one thing only: data.
Our recommendations are backed by hype or momentum – just numbers that show whether a company is a profit opportunity…
Or just another lame duck.
I’d love to have you with us for the next round of picks (which is set to come out soon) – which is why I’m inviting you now to become a member of GorillaTrades.
You don’t want to wait until this market has already heated up…
The time to move is now. So, make a choice!
Either way you choose, know we’re here if you ever need us.
That said, keep your eye on this hot market – it could be worth your while!
Until next time…
“Competition brings out the best in products and the worst in people.” — David Sarnoff
!function(f,b,e,v,n,t,s)
{if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};
if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′;
n.queue=();t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)(0);
s.parentNode.insertBefore(t,s)}(window, document,’script’,
‘https://connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘205349891423305’);
fbq(‘track’, ‘PageView’);
! function(f, b, e, v, n, t, s) {
if (f.fbq) return;
n = f.fbq = function() {
n.callMethod ?
n.callMethod.apply(n, arguments) : n.queue.push(arguments)
};
if (!f._fbq) f._fbq = n;
n.push = n;
n.loaded = !0;
n.version = ‘2.0’;
n.queue = ();
t = b.createElement(e);
t.async = !0;
t.src = v;
s = b.getElementsByTagName(e)(0);
s.parentNode.insertBefore(t, s)
}(window,
document, ‘script’, ‘https://connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘657700570932349’);
fbq(‘track’, “PageView”);